Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow PepGen Inc.

Get SEC filing alerts via email and in your feed for PepGen Inc.

PEPG

PepGen Inc.

About PepGen Inc.

PepGen Inc. is a biotechnology company developing oligonucleotide therapeutics using its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. Focused on neuromuscular and neurological diseases like Duchenne muscular dystrophy and myotonic dystrophy, it leverages cell-penetrating peptides to improve tissue delivery and efficacy. Its pipeline includes clinical-stage exon-skipping and splicing correction programs, aiming to address genetic root causes with enhanced safety, potency, and scalability.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from PepGen Inc.

1
1
PepGen Inc. PepGen Inc. Reports Improved Net Loss of $17.8 Million in Q1 2026

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
PepGen Inc. PepGen Inc. Reports $89.7 Million Net Loss for 2025, Advances PGN-EDODM1 in Clinical Trials

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
PepGen Inc. PepGen Inc. Reports Q3 2025 Financial Results with $18M Net Loss and Increased Total Assets

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
PepGen Inc. PepGen Inc. Reports $23.1 Million Net Loss in Q2 2025, Focuses on New Treatment Candidate

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
PepGen Inc. PepGen Inc. Reports $30.2 Million Net Loss in Q1 2025, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
PepGen Inc. PepGen Inc. Reports Financial Update, Advances Clinical Pipeline Despite Ongoing Losses

Via official filing (AI summary) | over 1 year ago | 0 comments